title: Circulating tumour necrosis factor alpha & soluble TNF receptors in patients with Guillain-Barre syndrome.
abstract: OBJECTIVE
  Tumour necrosis factor-alpha (TNF-alpha) is regarded as one of the immune factors that can induce demyelination of peripheral nerves in patients with Guillian-Barre syndrome (GBS). This present study was undertaken to find out the role of TNF-alpha and soluble TNF receptors in the pathogenesis of GBS; and to study the effect of intravenous immunoglobulin (ivIg) therapy on the serum TNF-alpha and soluble TNF receptors in patients with GBS.
  
  
  METHODS
  Thirty six patients with GBS in progressive stages of motor weakness were included in this study. The serum TNF-alpha and soluble TNF receptors (TNF-RI, TNF-RII) were measured in the serum samples of these patients before and after ivIg therapy by a sandwich ELISA.
  
  
  RESULTS
  Of the 36 patients with GBS, 26 (72.2%) showed elevated serum TNF-alpha levels prior to ivIg therapy. Following a complete course of ivIg therapy there was a progressive decrease in the serum TNF-alpha concentrations in these 26 patients. On the other hand, the soluble TNF receptors, particularly TNF-RII showed an increase in the serum of GBS patients following ivIg therapy.
  
  
  CONCLUSIONS
  The results indicate that ivIg reduces the serum TNF-alpha concentrations in the GBS patients having elevated levels prior to ivIg therapy. Elevated serum levels of soluble TNF receptors following ivIg therapy may play a protective role by inhibiting the demyelinating effect of TNF-alpha in the peripheral nerves of patients with GBS.
authors: Department of Pathology, Sree Chitra Tirunal Institute for Medical Sciences & Technology, Thiruvananthapuram, India.
authors: V V
authors: VV
authors: Radhakrishnan
authors: M G
authors: MG
authors: Sumi
authors: S
authors: S
authors: Reuben
authors: A
authors: A
authors: Mathai
authors: M D
authors: MD
authors: Nair
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D020275:Guillain-Barre Syndrome / Q000097:blood* / Q000276:immunology / Q000628:therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000378:metabolism*
chemical_list: D016756:Immunoglobulins, Intravenous; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha